findmyKOL
Clinical trialNCT03799731CompletedPhase 2Interventional

Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers

SponsorGamaMabs PharmaEnrollment65Colorectal Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Belgium
  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Uz Gasthuisberg

    Ghent, Belgium

  • Uz Leuven

    Leuven, Belgium

Czechia
  • University Hopistal Olomouc

    Olomouc, Czechia

  • University Hospital Motol

    Prague, Czechia

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

GM102GM102 expansionTrifluridine →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
11 Jul 2018
Primary completion
19 Jan 2021
Completion
10 Feb 2021
Last update posted
14 Apr 2022
Registered enrollment
65
Registry id
NCT03799731
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.